Korean skincare is everywhere on social media — but how much of it is backed by real dermatologic science? In this episode of The Science of Skin Podcast, Dr. Patti Farris sits down with Dr. Jane Yoo, board-certified dermatologist, fellowship-trained Mohs surgeon, and "The K-Beauty Dermatologist," to separate fact from TikTok fiction.

They trace K-beauty's roots from the Goryeo and Joseon dynasties through the Hallyu wave, then dig into the science: ceramide-dominant, barrier-centric formulations, low-pH cleansers, and why "glass skin" is more about consistent barrier care (and good lighting) than any single product. Dr. Yoo also breaks down the real evidence behind snail mucin, PDRN and PN, exosomes, and silica spicules — including where the hype outpaces the data — plus whether double cleansing is really necessary and why Korean sunscreen filters like bemotrizinol (Tinosorb S) may be the biggest public health advance in photoprotection in 25 years.

In this episode:

The real history of K-beauty, from royal court rituals to global export

What actually causes "glass skin" (and what doesn't)

The truth about snail mucin, PDRN/PN, exosomes, and spicules

Do you really need to double cleanse?

Why newly approved filters like bemotrizinol could change US sunscreens

Tinted, visible-light-blocking sunscreens for skin of color

Have a question or an idea for a future episode?

Email [email protected].

Join us at the Science of Skin Summit, September 17-20 in Austin, TX, or the new Science of Skin Longevity Conference in Scottsdale, February 2027.

Learn more at scienceofskinsummit.com

If you enjoyed this episode, please leave a 5-star rating and share with a colleague — word of mouth helps our podcast grow!

⚠️ This content is for educational and informational purposes only and reflects the personal clinical opinions and experiences of the speakers. It is not medical advice. Consult a licensed healthcare provider for questions about diagnosis or treatment.

In this episode of the Science of Skin Podcast, Dr. Patti Farris sits down with Dr. Dustin Portela and Mimi Banks (Principal, Mimi Banks Social) to talk all things DermFluencer University — the influencer education track heading into its third year at the Science of Skin Summit in Austin, TX (September 17–20).

Dustin and Mimi trace the program's origin from a single standing-room-only session to a full two-day experience combining a hands-on masterclass with practical, camera-ready workshops. They dig into why physicians need to show up in the spaces where health misinformation spreads — especially around topics like sunscreen and skin cancer — and share the systems, batching techniques, and content frameworks that make creating sustainable for busy clinicians.

The conversation also covers Med Creator 101, the podcast-turned-course born out of Dustin and Mimi's countless one-on-one conversations with physicians at AAD 2024, now distilled into an eight-module course covering everything from content hooks to HIPAA-conscious posting.

Whether you're a dermatologist, NP, PA, or aesthetician curious about content creation, this episode offers a behind-the-scenes look at how to build an authentic, science-backed presence online — imperfections and all.

Topics covered: DermFluencer University · Med Creator 101 · content batching & systems · combating skincare misinformation · camera presence & branding workshops · Science of Skin Summit 2026

In this special bonus episode of the Science of Skin Podcast, Dr. Patti Farris sits down with Dr. Sandra (Sandy) Johnson — private practice dermatologist in Fort Smith, Arkansas, and member of the American Academy of Dermatology's Board of Directors — for an urgent conversation on the CMS reimbursement cuts threatening the future of dermatology.

Dr. Johnson breaks down the three major proposals from CMS that could devastate dermatology practices nationwide: a proposed cut to the 25-modifier that would penalize combined evaluation-and-procedure visits, a potential overhaul of indirect practice expense calculations that could hit dermatology harder than most specialties, and an effort to remove the AMA's RUC representation — stripping physicians of their voice in how reimbursement values are set.

Beyond the policy breakdown, Dr. Johnson shares what the AAD is doing to fight back and exactly what members can do right now: submitting the 30-second advocacy letter through Voter Voice, rallying staff and patients to do the same, donating to SkinPAC, and attending this year's Legislative Conference in Washington, DC before the mid-September deadline.

This is a call to action for the entire dermatology community — because a united voice is the specialty's best defense.

Topics covered:

• The proposed 9–25% CMS reimbursement cuts
• The 25-modifier and what it means for combined visits
• Indirect practice expenses and why dermatology may be hit hardest
• Efforts to remove the AMA from the RUC
• How to take action: Voter Voice, SkinPAC, and the AAD Legislative Conference

Millions of people live with chronic spontaneous urticaria (CSU) — unpredictable hives and angioedema lasting six weeks or longer with no identifiable trigger. In this episode of the Science of Skin podcast, board-certified dermatologists Dr. Ted Lain and Dr. Michelle Tarbox (Chair, Department of Dermatology, Texas Tech University Health Sciences Center, and host of the Dermosphere podcast) break down what CSU actually is, why it's often misdiagnosed as an allergy, and how it's treated — from first-line antihistamines to omalizumab (Xolair) to the newest option: Rhapsido (remibrutinib), the first oral BTK inhibitor approved for CSU.

In this episode, you'll learn:

• How CSU is diagnosed and why it's classified as a skin disease, not a true allergy
• The autoimmune vs. autoallergic subtypes driving chronic hives and angioedema
• Why antihistamine updosing often falls short — and its impact on quality of life
• How BTK inhibitors like remibrutinib (Rhapsido) work differently than biologics like omalizumab
• Real patient stories on the toll of chronic hives, misdiagnosis, and finding relief

This episode is sponsored by Novartis with content independently created by the Science of Skin podcast:

Have a question or an idea for a future episode? Email us at [email protected].

If you enjoyed this episode, please subscribe, leave a five-star rating, and tell a colleague or friend — word of mouth is how this podcast grows.

Topics: chronic spontaneous urticaria, CSU, chronic hives, urticaria treatment, angioedema, BTK inhibitor, remibrutinib, Rhapsido, omalizumab, Xolair, antihistamine-resistant hives, dermatology podcast, autoimmune skin disease

Epiduo is now available over the counter — and in this full episode of the Science of Skin Podcast, board-certified dermatologists Dr. Ted Lain and Dr. Patti Farris break down everything you need to know about this fixed-dose combination acne treatment.

From the landmark phase 3 clinical trial data to real-world tolerability, scarring reduction, and the risks of compounded alternatives, this is the definitive deep dive on adapalene 0.1% and benzoyl peroxide 2.5%.

In this episode:
✅ Why Epiduo's move to OTC is a game-changer for acne patients facing prescription barriers
✅ Full breakdown of the 2009 phase 3 trial: 1,600+ patients, 60 study centers, 4 treatment cohorts
✅ 67% reduction in inflammatory lesions and 60% reduction in total lesion count by week 12
✅ IGA success rates — 35% achieved clear/almost clear skin vs. 22-24% with monotherapy alone
✅ Phase 3B international trial data across diverse Fitzpatrick skin types
✅ Excellent tolerability data — erythema, dryness, and irritation all rated below "mild"
✅ How Epiduo addresses the full acne lesion life cycle, including scarring and PIH
✅ Why formulation science and FDA-approved testing matter vs. compounded alternatives
✅ The CeraVe/Cetaphil CAMP regimen (cleanse, moisturize, protect) for acne patients
✅ Real-world pricing, dosing, and application tips for OTC Epiduo

This episode of the Science of Skin Podcast is sponsored by Galderma.

Have a question or an idea for a future episode? Email [email protected].

Join us at the Science of Skin Summit, September 17-20 in Austin, TX, or the new Science of Skin Longevity Conference in Scottsdale, February 2027. Learn more at scienceofskinsummit.com.

If you enjoyed this episode, please leave a 5-star rating and share with a colleague — word of mouth helps our podcast grow!

⚠️ This content is for educational and informational purposes only and reflects the personal clinical opinions and experiences of the speakers. It is not medical advice. Consult a licensed healthcare provider for questions about diagnosis or treatment.

Dr. Ted Lain welcomes Dr. Mona Shariari — Associate Clinical Professor of Dermatology at Yale School of Medicine, Associate Director of Clinical Trials at Central Connecticut Dermatology, and host of the Medical Sisterhood Podcast — for a deep dive into one of dermatology's most persistent challenges: polypharmacy and topical confusion.

Ted and Mona look back at the old-school regimens dermatologists used to write out — one topical for the face, another for the body, different products for weekdays versus weekends — and how that complexity set patients up for poor adherence and side effects like skin thinning and hypopigmentation from steroid overuse. They discuss why once-daily, non-steroidal options like roflumilast cream and foam have changed the equation, allowing head-to-toe use without the body surface area and duration limits that come with topical steroids.

Got a question or an idea for a future episode? Email [email protected]

Join us at the Science of Skin Summit in Austin, TX this September, and the Science of Skin Longevity Summit in Scottsdale, AZ in February 2027. Details at scienceofskinsummit.com

If you enjoyed this episode, please subscribe and leave a 5-star rating — word of mouth is how this podcast grows!

Follow and Listen to the Podcast Here:

🍎 Apple Podcasts — https://podcasts.apple.com/us/podcast/skincare-confidential/id1664286292

🎵 Spotify — https://open.spotify.com/show/033Vffp4W8A72pVRVaoWzs

📦 Amazon Music — https://music.amazon.com/podcasts/7de48e5e-f450-466b-a0f4-f2275b67757f/skincare-confidential

💚 iHeart Radio — https://www.iheart.com/podcast/269-the-science-of-skin-269540115/

📻 Audacy — https://www.audacy.com/podcast/skincare-confidential-4398f

#Dermatology #Roflumilast #EczemaTreatment #PsoriasisTreatment #SeborrheicDermatitis #AtopicDermatitis #TopicalSteroids #SteroidStewardship #NonSteroidalTreatment #PediatricDermatology #DermatologyPodcast #ScienceOfSkin #YaleDermatology #SkinHealth

Dr. Ted Lain welcomes Dr. Mona Shariari — Associate Clinical Professor of Dermatology at Yale School of Medicine, Associate Director of Clinical Trials at Central Connecticut Dermatology, and host of the Medical Sisterhood Podcast — for a deep dive into one of dermatology's most persistent challenges: polypharmacy and topical confusion.

Ted and Mona look back at the old-school regimens dermatologists used to write out — one topical for the face, another for the body, different products for weekdays versus weekends — and how that complexity set patients up for poor adherence and side effects like skin thinning and hypopigmentation from steroid overuse. They discuss why once-daily, non-steroidal options like roflumilast (Zoryve) cream and foam have changed the equation, allowing head-to-toe use without the body surface area and duration limits that come with topical steroids.

Topics covered include:

Why systemic absorption is a bigger concern with topical steroids in pediatric patients

Clinical trial insights on roflumilast for seborrheic dermatitis, atopic dermatitis, and psoriasis

The foam formulation's use in sensitive areas like the scalp, face, and skin folds

How roflumilast compares to older PDE4 inhibitors and topical calcineurin inhibitors

Why the drug's mechanism works across both TH1- and TH2-driven inflammation

The impact of once-daily dosing on patient compliance and long-term outcomes

Practical tips for talking to patients transitioning off topical steroids

This episode is sponsored by Arcutis Biotherapeutics, makers of Zoryve (roflumilast).

Got a question or an idea for a future episode? Email [email protected]

Join us at the Science of Skin Summit in Austin, TX this September, and the Science of Skin Longevity Summit in Scottsdale, AZ in February 2027. Details at scienceofskinsummit.com

If you enjoyed this episode, please subscribe and leave a 5-star rating — word of mouth is how this podcast grows!

Are topical steroids doing more harm than good? Board-certified dermatologist Dr. Ted Lain sits down with Dr. Allie Golant, Associate Professor and Vice Chair of Dermatology at Mount Sinai, to unpack the real risks of topical corticosteroids — and why steroid stewardship is becoming a bigger conversation in dermatology.

Got a question or topic idea? Email us at [email protected]

Join us at the Science of Skin Summit — Austin, TX, September 2026, and our Longevity Meeting in Scottsdale, AZ, February 2027. Details at scienceofskinsummit.com

If you enjoyed this episode, please subscribe, leave a 5-star rating, and share it with a colleague — word of mouth is how this podcast grows!

Follow and Listen to the Podcast Here:

🍎 Apple Podcasts — https://podcasts.apple.com/us/podcast/skincare-confidential/id1664286292

🎵 Spotify — https://open.spotify.com/show/49NtbRxb32CJu2XtSV6tso

📦 Amazon Music — https://music.amazon.com/podcasts/7de48e5e-f450-466b-a0f4-f2275b67757f/skincare-confidential

💚 iHeart Radio — https://www.iheart.com/podcast/269-the-science-of-skin-269540115/

📻 Audacy — https://www.audacy.com/podcast/skincare-confidential-4398f

👉 Subscribe for weekly dermatology deep dives

👉 New episodes cover skincare science, dermatology treatments, and skin health for the whole family

Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.

#TopicalSteroids #Dermatology #EczemaTreatment #PsoriasisTreatment #SkinOfColor #AtopicDermatitis #SteroidStewardship #NonSteroidalTreatment #DermatologyPodcast #SkinHealth #Hypopigmentation #ScienceOfSkin #DermTok #SkincareScience

Are topical steroids doing more harm than good? Board-certified dermatologist Dr. Ted Lain sits down with Dr. Allie Golant, Associate Professor and Vice Chair of Dermatology at Mount Sinai, to unpack the real risks of topical corticosteroids — and why steroid stewardship is becoming a bigger conversation in dermatology.

In this episode, you'll learn:

Why topical steroid overuse leads to skin thinning, striae, and hypopigmentation — especially in skin of color patients

The dangers of "polypharmacy" when patients mix and match steroid potencies across body areas

How systemic steroid absorption can affect bone density, endocrine health, and even eye pressure

Why steroid stewardship matters across specialties, not just dermatology

How non-steroidal alternatives like Zoryve (roflumilast) cream and foam are changing treatment for eczema and psoriasis

Practical tips for talking to patients about safer, simplified treatment regimens

This episode is sponsored by Arcutis Biotherapeutics, makers of Zoryve.

Got a question or topic idea? Email us at [email protected]

Join us at the Science of Skin Summit — Austin, TX, September 2026, and our Longevity Meeting in Scottsdale, AZ, February 2027. Details at scienceofskinsummit.com

If you enjoyed this episode, please subscribe, leave a 5-star rating, and share it with a colleague — word of mouth is how this podcast grows!

Dr. Ted Lain and Dr. Patti Farris cut through the hype around today's most popular longevity supplements.

They dig into the real (and often surprisingly thin) clinical evidence behind NAD precursors like NMN and nicotinamide riboside, the gut-derived compound Urolithin A, creatine for brain and muscle health, multivitamins and the buzzy Cosmos trial, and off-label rapamycin use.

Along the way, they talk through epigenetic clocks, precision medicine, why mouse studies don't always translate to humans, and why "TBD" might be the most honest verdict on longevity science right now.

Plus, details on their upcoming Science of Skin Longevity Summit, February 19–21, 2027, in Scottsdale, Arizona.

Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.